EUVIMEDEUVIMED entdecken
Crossref

Nicardipine-chitosan nanoparticles alleviate thioacetamide-induced acute liver injury by targeting NFκB/NLRP3/IL-1β signaling in rats: Unraveling new roles beyond calcium channel blocking

Ahmed Y Kira, Elsayed A Elmorsy, Rabab S Hamad, Mustafa Ahmed Abdel-Reheim, Mai Abdallah Elhemely, Noura El Adle Khalaf, Attalla F El-Kott, Mohammed A AlShehri, Kareem Morsy, Sally Negm, Ahmed A E Mourad, Asmaa Ramadan und 1 weitere

International Immunopharmacology · 2024-11 · 141 · 113000

DOI: 10.1016/j.intimp.2024.113000 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024-11. Verfasst von Ahmed Y Kira und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt. Electronic address: Ahmed.kira@de…. Hauptthemen laut MEDLINE: Chitosan, NLR Family, Pyrin Domain-Containing 3 Protein, Nanoparticles, NF-kappa B. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver inflammatory diseases are marked by serious complications. Notably, nicardipine (NCD) has demonstrated anti-inflammatory properties, but its benefits in liver inflammation have not been studied yet. However, the therapeutic efficacy of NCD is limited by its short half-life and low bioavailability. Therefore, we aimed to evaluate the potential of NCD-loaded chitosan nanoparticles (ChNPs) to improve its pharmacokinetic profile and hepatic accumulation. Four formulations of NCD-ChNPs were synthesized and characterized. The optimal formulation (NP2) exhibited a mean particle diameter of 172.6 ± 1.94 nm, a surface charge of +25.66 ± 0.93 mV, and an encapsulation efficiency of 88.86 ± 1.17 %. NP2 showed good physical stability as a lyophilized powder over three months. It displayed pH-sensitive release characteristics, releasing 77.15 ± 5.09 % of NCD at pH 6 (mimicking the inflammatory microenvironment) and 52.15 ± 3.65 % at pH 7.4, indicating targeted release in inflamed liver tissues. Pharmacokinetic and biodistribution studies revealed that NCD-ChNPs significantly prolonged NCD circulation time and enhanced its concentration in liver tissues compared to plain NCD. Additionally, the study investigated the protective effects of NCD-ChNPs in thioacetamide-induced liver injury in rats by modulating the NFκB/NLRP3/IL-1β signaling axis. NCD-ChNPs effectively inhibited NFκB activation, reduced NLRP3 inflammasome activation, and subsequent release of IL-1β, which correlated with improved hepatic function and reduced inflammation and oxidative stress. These findings highlight the potential of NCD-ChNPs as a promising nanomedicine strategy for the treatment of liver inflammatory diseases, warranting further investigation into their clinical applications, particularly in hypertensive patients with liver inflammatory conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChitosanNLR Family, Pyrin Domain-Containing 3 ProteinNanoparticlesNF-kappa BInterleukin-1betaThioacetamideNicardipineSignal TransductionChemical and Drug Induced Liver InjuryAnimalsMaleRatsLiverCalcium Channel BlockersRats, Sprague-DawleyAnti-Inflammatory AgentsTissue Distribution

Stichwörter der Autor:innen

Chitosan nanoparticlesLiver biodistributionLiver inflammatory diseasesNFκB/NLRP3/IL-1β signalingNew therapeutic targetNicardipine

Substanzen

ChitosanNLR Family, Pyrin Domain-Containing 3 ProteinNF-kappa BNlrp3 protein, ratInterleukin-1betaThioacetamideNicardipineCalcium Channel BlockersAnti-Inflammatory AgentsIL1B protein, rat

Autor:innen und Institutionen

  • Department of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt. Electronic address: Ahmed.kira@deltauniv.edu.eg.
  • Department of Pharmacology and Therapeutics, College of Medicine, Qassim University, Buraidah 51452, Saudi Arabia. Electronic address: a.almarsa@qu.edu.sa.
  • Biological Sciences Department, College of Science, King Faisal University, Al Ahsa 31982, Saudi Arabia; Central Laboratory, Theodor Bilharz Research Institute, Giza 12411, Egypt. Electronic address: rhamad@kfu.edu.sa.
  • Department of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Shaqra 11961, Saudi Arabia. Electronic address: m.ahmed@su.edu.sa.
  • School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M20 4BX, UK; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni Suef…
  • Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt. Electronic address: nouraeladle@mans.edu.eg.

Zitieren

APA

Kira, A. Y., Elmorsy, E. A., Hamad, R. S., Abdel-Reheim, M. A., Elhemely, M. A., El Adle Khalaf, N., El-Kott, A. F., AlShehri, M. A., Morsy, K., Negm, S., Mourad, A. A. E., Ramadan, A., & Saber, S. (2024). Nicardipine-chitosan nanoparticles alleviate thioacetamide-induced acute liver injury by targeting NFκB/NLRP3/IL-1β signaling in rats: Unraveling new roles beyond calcium channel blocking. International Immunopharmacology, 141, 113000. https://doi.org/10.1016/j.intimp.2024.113000

Vancouver

Kira AY, Elmorsy EA, Hamad RS, Abdel-Reheim MA, Elhemely MA, El Adle Khalaf N, et al. Nicardipine-chitosan nanoparticles alleviate thioacetamide-induced acute liver injury by targeting NFκB/NLRP3/IL-1β signaling in rats: Unraveling new roles beyond calcium channel blocking. International Immunopharmacology. 2024;141:113000. doi:10.1016/j.intimp.2024.113000

BibTeX
@article{Kira2024,
  author = {Kira, Ahmed Y and Elmorsy, Elsayed A and Hamad, Rabab S and Abdel-Reheim, Mustafa Ahmed and Elhemely, Mai Abdallah and El Adle Khalaf, Noura and El-Kott, Attalla F and AlShehri, Mohammed A and Morsy, Kareem and Negm, Sally and Mourad, Ahmed A E and Ramadan, Asmaa and Saber, Sameh},
  title = {Nicardipine-chitosan nanoparticles alleviate thioacetamide-induced acute liver injury by targeting NFκB/NLRP3/IL-1β signaling in rats: Unraveling new roles beyond calcium channel blocking},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {141},
  pages = {113000},
  doi = {10.1016/j.intimp.2024.113000}
}
Kostenlos starten →